Complete Electroanatomic Imaging of the Diastolic Pathway Is Associated With Improved Freedom From Ventricular Tachycardia Recurrence.
Action Potentials
Aged
Cardiac Catheters
Catheter Ablation
/ adverse effects
Diastole
Disease-Free Survival
Electrophysiologic Techniques, Cardiac
/ instrumentation
Female
Heart Rate
Humans
Male
Middle Aged
Predictive Value of Tests
Recurrence
Retrospective Studies
Risk Factors
Tachycardia, Ventricular
/ diagnosis
Time Factors
ablation
catheter ablation
mapping
recurrence
ventricular tachycardia
Journal
Circulation. Arrhythmia and electrophysiology
ISSN: 1941-3084
Titre abrégé: Circ Arrhythm Electrophysiol
Pays: United States
ID NLM: 101474365
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
7
8
2020
medline:
16
3
2021
entrez:
7
8
2020
Statut:
ppublish
Résumé
The development of multielectrode mapping catheters has expanded the spectrum of mappable ventricular tachycardias (VTs). Full diastolic pathway recording has been associated with a high rate of VT termination during radiofrequency ablation as well as noninducibility at study end. However, the role of diastolic pathway mapping on VT recurrence has yet to be clearly elucidated. We aimed to explore the role of complete diastolic pathway activation mapping on VT recurrence. Eighty-five consecutive patients who underwent VT ablation guided by high-density mapping were enrolled. During activation mapping, the presence of electrical activity in all segments of diastole defined the evidence of having had recorded the whole diastolic interval. Patients were categorized as having recorded the full diastolic pathway, partial diastolic pathway, or no diastolic pathway map performed. Recurrences of VT were defined as appropriate implantable cardioverter defibrillator therapies or on the basis of ECG-documented arrhythmia. Eighty-five patients were included. Complete recording of the diastolic pathway was achieved in 36/85 (42.4%) patients. Partial recording of the diastolic pathway of the clinical VT was achieved in 24/85 (28.2%) patients. No recording of the diastolic pathway of the clinical VT was feasible in 25/85 patients (29.4%). At a mean of 12.8 months, freedom from VT recurrence was 67% in the overall cohort. At a mean of 12.8 months, freedom from VT recurrence was 88%, 50%, and 55% in patients who had full diastolic activity recorded, partial diastolic activity recorded, or underwent substrate modification, respectively; the observed differences were statistically significant ( Mapping of the entire diastolic pathway was associated with a higher freedom from VT recurrence as compared with partial diastolic pathway recording and substrate modification. The use of multielectrode mapping catheters in recording diastolic activity may help predict those VTs employing intramural circuits and further optimize ablation strategies.
Sections du résumé
BACKGROUND
The development of multielectrode mapping catheters has expanded the spectrum of mappable ventricular tachycardias (VTs). Full diastolic pathway recording has been associated with a high rate of VT termination during radiofrequency ablation as well as noninducibility at study end. However, the role of diastolic pathway mapping on VT recurrence has yet to be clearly elucidated. We aimed to explore the role of complete diastolic pathway activation mapping on VT recurrence.
METHODS
Eighty-five consecutive patients who underwent VT ablation guided by high-density mapping were enrolled. During activation mapping, the presence of electrical activity in all segments of diastole defined the evidence of having had recorded the whole diastolic interval. Patients were categorized as having recorded the full diastolic pathway, partial diastolic pathway, or no diastolic pathway map performed. Recurrences of VT were defined as appropriate implantable cardioverter defibrillator therapies or on the basis of ECG-documented arrhythmia.
RESULTS
Eighty-five patients were included. Complete recording of the diastolic pathway was achieved in 36/85 (42.4%) patients. Partial recording of the diastolic pathway of the clinical VT was achieved in 24/85 (28.2%) patients. No recording of the diastolic pathway of the clinical VT was feasible in 25/85 patients (29.4%). At a mean of 12.8 months, freedom from VT recurrence was 67% in the overall cohort. At a mean of 12.8 months, freedom from VT recurrence was 88%, 50%, and 55% in patients who had full diastolic activity recorded, partial diastolic activity recorded, or underwent substrate modification, respectively; the observed differences were statistically significant (
CONCLUSIONS
Mapping of the entire diastolic pathway was associated with a higher freedom from VT recurrence as compared with partial diastolic pathway recording and substrate modification. The use of multielectrode mapping catheters in recording diastolic activity may help predict those VTs employing intramural circuits and further optimize ablation strategies.
Identifiants
pubmed: 32755381
doi: 10.1161/CIRCEP.120.008651
pmc: PMC7495983
doi:
Types de publication
Journal Article
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
e008651Références
Arrhythm Electrophysiol Rev. 2015 Dec;4(3):177-83
pubmed: 26835122
Circ Arrhythm Electrophysiol. 2014 Jun;7(3):424-35
pubmed: 24833642
Circulation. 2013 Apr 2;127(13):1359-68
pubmed: 23439513
HeartRhythm Case Rep. 2015 Nov 16;1(6):397-400
pubmed: 28491595
Circ Arrhythm Electrophysiol. 2015 Apr;8(2):390-9
pubmed: 25740836
N Engl J Med. 2016 Jul 14;375(2):111-21
pubmed: 27149033
Heart Rhythm. 2015 Sep;12(9):1997-2007
pubmed: 26031376
J Am Coll Cardiol. 2015 Dec 29;66(25):2872-2882
pubmed: 26718674
Arrhythm Electrophysiol Rev. 2019 Mar;8(1):54-59
pubmed: 30918668
Circ Arrhythm Electrophysiol. 2015 Aug;8(4):853-62
pubmed: 25969540
J Interv Card Electrophysiol. 2020 Sep;58(3):365-367
pubmed: 32440944
Heart Rhythm. 2020 Mar;17(3):439-446
pubmed: 31622782
Circ Arrhythm Electrophysiol. 2018 Mar;11(3):e005602
pubmed: 29545359
Circ Arrhythm Electrophysiol. 2019 Sep;12(9):e007500
pubmed: 31500436
J Am Coll Cardiol. 2020 Mar 3;75(8):884-897
pubmed: 32130924